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ABSTRACT
DOES THE METHOD OF TREATING BACTERIAL VAGINOSIS IN
EARLY PREGNANCY AFFECT THE REOCCURRENCE RATE NEAR TERM?
By
Karen 5. Taylor
There is no significant difference in the relationship
between oral or vaginal metronidazole and oral clindamycin
in the treatment of bacterial vaginosis

(BV) in early

pregnancy and the reoccurrence rate of BV at 35 to 37 weeks
gestation.

Treatment of BV in pregnancy has been shown to

decrease the preterm delivery rate saving millions of
dollars and improving the health of infants. This was a
descriptive, correlational study using a retrospective
chart review.

A constructed checklist was used for

collecting data from 18 6 charts.
Age, parity, and insurance were comparable in each of
the three drug groups. The reoccurrence rate of BV when
tested in the third trimester showed no significant
differences in comparison of the three drug treatment
groups (Chi-square = .55; df = 2; p = .76).

All three

drugs were equally effective in the treatment of BV.
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Chapter One
INTRODUCTION
Preterm births continue to be the most significant
pregnancy related problem in the United States.
Prematurity is responsible for almost 75% of neonatal
mortality and as much as 50% of long term neurological
damage in children (Hauth, Goldenberg, Andrews, DuBard, &
Copper 1995).

Reports have shown one-fifth of children

weighing less than lOGOg at birth have moderate to severe
neurosensory handicaps at 2 years of age (Novy, McGregor, &
lams 1995).

Handicaps can include blindness, deafness,

mental retardation, epilepsy, and cerebral palsy.

In 1990

the costs for special education for 85,000 preterm children
in the United States was $370 million (Novy et al.). As of
1994, the United States ranked 22 out of 18 6 in world
infant mortality rates.

Many feel the poor ranking is due

to the high number of premature births and low birth weight
infants born here.

Preterm birth rates remained relatively

constant for 40 years until the 1980s.

There has been a

slow rise in rates especially in certain groups of women.
Nurse practitioners frequently make decisions on
desired drug treatment given to obstetrical patients;
therefore, they have the ability to have a positive
influence on the preterm delivery rate.

Prevention of

preterm deliveries is of utmost importance worldwide,
because it not only will improve the health of many
children but also will also save billions of dollars spent
on their healthcare.

Early identification and optimal

treatment of bacterial vaginosis has the potential to
decrease the incidence of preterm labor (Hack & Merkatz,
1995).
Why do preterm birth rates continue to rise despite
hundreds of preventative interventions throughout the
world?

Programs such as early prenatal care, better

nutrition, easier access to health care, increased social
support, home uterine monitoring, increased education of
patients and about tocolytic drugs have been shown to be
unsuccessful in affecting the overall rate of preterm
births (Goldenberg & Andrews, 1996).

Therefore,

researchers are focusing more on the reasons why preterm
labor happens versus how to stop labor once it occurs.
Numerous studies have shown that bacterial vaginosis (BV)
has been a common link to labor before 37 weeks
al. 1995).

(Hillier et

BV is one of the most common genital tract

infections found in women.

Up to 22% of pregnant women

have this infection present at their initial examination
(Hillier et al.).

Chorioamnionitis is commonly caused by

BV and is found in up to 80% of deliveries prior to 30

weeks gestation (Goldenberg & Andrews).
Bacterial vaginosis is an overgrowth of normal
vaginal organisms.

It begins in the lower genital tract

and often ascends through the cervix to the uterus
affecting the pregnancy.

Even after adjustment for

variables such as previous preterm delivery or maternal
weight below 110 lbs, women with BV are 40% more likely to
give birth before term (Hillier et al, 1995).

One study in

Indonesia showed the rates of preterm delivery were almost
doubled for those diagnosed with BV in the early second
trimester (20.5%) as compared with those diagnosed in late
pregnancy (10.7%)

(Riduan et al. 1993).

Antimicrobial therapy given to pregnant women positive
for BV in the second trimester decreases the risk of
preterm delivery (Hauth et al. 1995). Currently there are
four primary antibiotic treatments used.

Metronidazole has

always been the drug of choice for treatment of BV in the
non-pregnant woman.

Many practitioners are reluctant to

use metronidazole in the pregnant patient because of the
possible mutagenic and/or carcinogenic effects in the
infant, especially in the first trimester.

A recent meta

analysis does not show teratogenicity in humans

(Centers

for Disease Control and Prevention, 1998). Centers for
Disease Control (CDC) treatment guidelines for 1998

continue to recommend oral metronidazole as the drug of
choice in the treatment of BV.

Other drug choices include

oral clindamycin, metronidazole vaginal gel 0.75%, and
clindamycin 2% vaginal cream. CDC guidelines no longer
recommend clindamycin vaginal cream during pregnancy due to
recent studies indicating an increase in the rate of
preterm births with its use.
Much discussion has taken place on which drug
treatment is the most effective in eradicating the
infection.

Once the microorganisms ascend the upper

reproductive tract, intravaginal medications may not be
helpful to prevent preterm deliveries.

Thus, the CDC

(1998) no longer recommends intravaginal treatments for
pregnant women who have previously delivered a premature
infant.

Studies vary slightly on the effectiveness rates

of the above mentioned antibiotics.

Joesoef and Schmid

(1995) found no significant difference in efficacy between
oral metronidazole and oral clindamycin (96% vs 94%).
Ferris, Litaker, Woodward, Mathis, and Hendrich (1995)
reported similar findings. Some clinicians are hesitant to
use clindamycin due to possible gastrointestinal problems
including pseudomembranous colitis
10%)

(Reynolds, 1991) .

(occurrence rate 2% to

Recommended doses for the treatment

of BV in pregnancy are well within dosage guidelines.

Due

to the fact that many clinical practices may not reevaluate
the patient unless symptomatic, the most effective drug
should be used if possible in order to increase the patient
cure rate. Many times nurse practitioners are the primary
providers for identification and treatment of bacterial
vaginosis.

Nurse practitioners may not only save lives of

infants born too early, but also save millions of dollars
through decreased hospitalizations and long term care.
The purpose of this study was to examine differences
in the relationship between oral metronidazole, vaginal
metronidazole or oral clindamycin treatment of BV in early
pregnancy (before 16 weeks) and the recurrence rate of BV
at 35 to 37 weeks gestation.

Chapter Two
CONCEPTUAL FRAMEWORK
The conceptual framework for examining the
relationship between treatment method for BV in early
pregnancy and the recurrence rate near term will be based
on the Betty Neuman Health Care Systems Model (Neuman/
1989).

Neuman began developing her theory in the late

1960s in response to requests from graduate students
(Beckman,- 1994) .

Her completed conceptual model was

presented in 1970 and has been further developed several
times since then (Beckman).

The model is a product of her

philosophy and observations made in teaching mental health
nursing and in counseling (Neuman).
Neuman labels her systems theory as a general theory
involving an open system approach.

Neuman's systems model

incorporates stress as the deciding factor for all
interventions for the self or environment.

Neuman (1993)

believes a person's health centers around stressors and
coping.
death.

Inability to cope results in illness and sometimes
The self is in constant interaction with the

environment.

The goal of the intervention is to strengthen

the basic structure (the self) so that the effect of the
stressor is minimized (Bullock, 1993).
Neuman's model contains several circles or rings

around the self(See Figure 1).

The rings differ for each

person because they include information from physiologic,
psychologic,
attributes

sociocultural, developmental, and spiritual

(Bullock, 1993).

flexible line of defense.

The outermost ring is the
It expands to provide increased

protection and contracts for less protection of the self or
core.

The flexible line of defense represents the

immediate responses an individual makes to actual or
potential stressors.

Distance of the stressors from the

core varies according to the needs and abilities of the
client.

Stressors vary with age, health status,

educability and resources.
normal line of defense.

The next inner ring is the

This represents a stability state,

baseline or standard, which develops over time.
The innermost circles are called the lines of
resistance and are the body's attempt to stabilize against
the disequilibrium caused by the stressor (Bullock, 1993).
The lines of resistance include those things an individual
does at a conscious or subconscious level to restore
equilibrium or achieve an even higher level of stability.
The lines of resistance include prevention at primary,
secondary, and tertiary levels.

Educating a woman on how

to reduce her risk factors for BV (e.g. frequent partners,
smoking, and douching) is an example of primary

Flexible Line of Defsnse

frequent partnets
douching
smoking
multigravida
underlSyroid

Lines of Resistefice
Primaiy ,
Secondary
Tertiary '

^\e>dl^ L in e ofDefensft
Une of

Normal Line of Defense

Vaginal
ecosystem

Figure 1.

Neuman's Systems Model
Neuman (198 9)

prevention.

Secondary prevention involves interventions or

treatments initiated after symptoms have occurred.
would include antibiotic treatment of BV.

This

Tertiary

intervention occurs after actual treatment.

The goal of

tertiary intervention is reconstitution of the woman to an
optimal level of health (Bullock, 1993).

Exploring ways to

decrease the recurrence of BV would be an example of
tertiary intervention.

It focuses on readjustment toward

optimal stability.
The inner most ring is the core.

The core is

represented by a solid line to indicate its stability.

The

core consists of those things necessary for survival such
as temperature and organ function.

The person's individual

genetic makeup, such as weaknesses and strengths of
different body parts, ego, and response patterns also
affect the core.

The core may also represent a family,

group or community.

Penetration of the core could lead to

death or destruction. Strengthening the lines of defense
and the lines of resistance helps to protect the core.
In summary, Neumans Systems Model (198 9) is a holistic
model which addresses the social, developmental,
psychological, physical, and spiritual aspects of the
pregnant woman and how they are impacted by stressors.

The

rings of resistance protect the inner core of the woman and

her pregnancy.

Bacterial vaginosis may weaken the flexible

line of defense leading to pelvic infections, premature
rupture of membranes or preterm labor.

Treating the

pregnant patient with the most effective antibiotic will
help her to strengthen her lines of resistance and
reestablish her normal line of defense.
Review of Literature
The vaginal ecosystem is the normal line of defense.
Lactobacilli, a Gram positive bacilli, dominate other
vaginal microorganisms to maintain a healthy genital tract
through maintenance of pH and generation of antimicrobial
hydrogen peroxide (Overman, 1993).

Eschenbach and Mead

(1992) reported that 96% of normal women were found to have
peroxide-producing lactobacilli.

Vaginosis is an imbalance

of this ecosystem associated with decreased numbers of
lactobacilli and increased Gram-negative organisms.

The

normal vaginal ecosystem may be influenced by the menstrual
cycle, pregnancy, menopause, contraceptive methods,
douching, use of antibiotics, disease, stress, frequent
intercourse, and trauma.
Lactobacilli control the lower genital tract by two
mechanisms, primarily by producing a by-product called
lactic acid.

It is thought that conversion of glycogen

from vaginal epithelial cells creates lactic acid (Overman,
10

1993).

Lactic acid produces an optimal acidic environment

that limits the growth of microorganisms rec[uiring an
alkaline environment to survive.

The second feature is the

production of hydrogen peroxide by the lactobacilli.
Peroxidases are found in white blood cells, mucus, and
vaginal secretions, and halides are found in cervical mucus
(Overman, 1993) .

Hydrogen peroxide, peroxidase, and

halide are normally present in the healthy female genital
tract.

Together they create a environment toxic to many

potential pathogens.
According to Reynolds (1991), Gardner and Dukes were
first to identify bacterial vaginosis in 1955.

Initially

it was called Haemophilus vaginalis due to its appearance
like the Haemophilus genus.
called the infection

Until this time, clinicians

"nonspecific vaginitis".

Over the

years, it has assumed several other names as more
information unfolded as to the particulars of the infection
and criteria for diagnosis.

When the organism resembled

the genus Corynehacterlum rather than Haemophilus, the name
changed to Corynehacterlum vaginalis

(Reynolds) . Anaerobic

vaginitis was another descriptive name given due to the
high levels of Gram-negative anaerobes
1996) .

(Ament & Whalen,

Probably the most recognized name is Gardnerella

vaginalis (named for its discoverer, Gardner) .
11

The current

term is bacterial vaginosis or BV.
All the organisms associated with bacterial vaginosis
are found normally in the vagina.

In women with BV, the

normal vaginal ecosystem is altered from one with high
concentrations of hydrogen peroxide producing lactobacilli
to one with high concentrations of Gram-negative anaerobes
and other bacteria (Freeman, 1995).

These bacteria can

increase 100 to 1000 fold over what they would be normally
(Hillier, 1995).

Bacteria can include Bacteroides species,

Mobiluncus species, Gardnerella vaginalis, and Mycoplasma
homlnls.

Anaerobes produce amines such as putrescine and

cadaverine which raise the pH to an alkaline level,
promoting overgrowth and causing an unpleasant odor
(Handsfield, 1992).
Bacterial vaginosis is a noninflammatory response to
the change in the vaginal ecosystem.

Women will quite

frequently have no symptoms of infection.

Reported

symptoms can include frothy, watery, milky gray or yellow
homogenous discharge.

Often, a characteristic foul fishy

odor is present also (Moore & Freda, 1998).
Diagnosis of BV can usually be made with microscopic
examination of vaginal secretions during a clinical visit.
The test is easy, inexpensive, and accurate.

Two slides

are prepared with one drop of vaginal discharge on each.
12

Each slide is examined at lOX and 40X.
mixed with normal saline.

The first sample is

In BV, clue cells, coccobacilli

adhering to squamous epithelial cells, give them a
peppered" appearance.

Lactobacillus, normally visible in

abundant numbers, are greatly reduced or absent.

A drop of

10% potassium hydroxide (KOH) is added to the second slide.
Potassium hydroxide volatilizes the amines, putrescine, and
cadaverine giving off a fishy, ammonia-like odor.
same amines are found in rotting fish.
present in 90% of BV infections

These

This odor is

(Eschenbach & Mead, 1992).

Due to the likelihood of an alkaline environment with
BV, pH should also be done to confirm the diagnosis.
Bacterial vaginosis generally has a pH greater than 4.5.
Normal vaginal pH is between 3.0 and 4.0.

Gram staining is

another option if the diagnosis is inconclusive. Vaginal
secretions are rolled onto a glass slide and heat fixed or
air dried.

The smear is then stained with Gram stain by

the usual Gram stain procedure.

Bacteria that remain

purple are Gram positive and those which stain red are Gram
negative.

Vaginal cultures, although more expensive, can

also be done.
The origins of bacterial vaginosis are not well
understood.

Although there is an increased incidence in

women with multiple sex partners, it is not considered to
13

be sexually transmitted.

Young girls and virginal women

have been diagnosed with BV.

Other risk factors may

include low socioeconomic status, frequent douching,
increased parity, smoking, young age. Black race, frequent
intercourse, and condom use (Morales et al, 1994) .

A study

in Milwaukee reported 33% of pregnant adolescents tested
positive for BV (Ament & Whalen, 1996).

Hauth and

coworkers (1995) reported that Black women had nearly three
times as much BV as white women.

The use of intrauterine

devices also increases the risk of infection.
'‘How does Gaxdernella vaginalis get into the uterus
during pregnancy?"

Two theories are suggested.

The first

explanation is that the bacteria are already present in the
uterus prior to pregnancy.

This colonization often causes

an asymptomatic endometritis.

The infection remains low

key until the membranes adhere to the decidual lining of
the uterus at about 20 weeks gestation, sealing the uterus
closed (Goldenberg & Andrews, 1996).

The second theory is

that lower genital tract bacteria ascend through the
cervical canal to the uterus. Novy et al.(1995) stated that
organisms associated with BV have been recovered from the
amniotic fluid in 5-20% of women in preterm labor with
intact membranes.
Elevated by-products of BV such as vaginal or cervical
14

endotoxin, lancinase, sialidase, and interleukin-Al are
thought to produce inflaimaatory cytokines
1995).

(Hillier et al.

Arachidonic acid metabolites called eicosanoids are

also produced (Novy et al. 1995).

Eicosanoids are involved

in the biosynthesis of prostaglandins and leukotrienes.
Women with cervical dilation and amnionic infection have
higher levels of cytokines and prostaglandins
al.).

(Novy et

The role of prostaglandins in cervical dilatation

and effacement has been well documented (Reynolds, 1991) .
It has been suggested that inflammatory cells produce
proteases which may overpower mucous membranes and weaken
the connective tissue strength of the chorioamnion and
cervix (Novy et al.) . The connective tissue is an example
of the flexible line of defense. The weakened state can
lead to premature rupture of placental membranes or
cervical dilatation.
Metronidazole has been the drug of choice for the
treatment of BV since the 1980s. It is a member of the
imidazole class of antibacterial drugs.

Metronidazole is

believed to reduce its nitro group under anaerobic
conditions which leads to cytotoxic products that interfere
with the DNA and kill the bacteria (Murphy & Jones, 1994) .
More than half of the drug is broken down in the liver.
This breakdown produces metabolites that also kill
15

bacteria. Lactobacilli are not affected by the drug, which
allows the vaginal ecosystem to return to normal.

Peak

serum levels of 20-25 ug/ml are achieved in one to three
hours unless taken with a meal (Peppercorn, Shelley, &
Sobel, 1993).
hours.

Serum half-life varies from 6 to 12

Metronidazole passes through the placenta and can

be found in fetal tissue and amniotic fluid (Murphy &
Jones).

It is also found in breast milk in concentrations

equal to serum levels

(Murphy & Jones).

Side effects may

include gastrointestinal upset, nausea, metallic taste,
vaginal burning, sleeplessness, headache and ataxia.
Metronidazole should not be used concomitantly with
disulfiram (Antabuse) which can cause respiratory
depression, cardiovascular collapse, arrhythmias,
myocardial infarction, acute heart failure, seizures,
unconsciousness, or death.
Many clinicians are reluctant to use metronidazole
during pregnancy due to q[uestions regarding possible
carcinogenic and teratogenic effects.

Metronidazole was

shown to be nonteratogenic in rats, mice, and guinea pigs
and carcinogenicity has never been reported in humans
(Burtin, Taddio, Ariburnu, Einarson, & Gideon, 1995).
meta-analysis performed by Burtin et al.

A

(1995) reported

that the use of metronidazole in pregnant women does not
16

appear to increase teratogenicity.

Burtin et al. reviewed

all medical literature published on metronidazole use
during pregnancy since its release in 1959.

Thirty-two

articles were found that reported original data.

Oral

metronidazole or a combination of oral and vaginal
metronidazole was used for treatment courses lasting 7 to
10 days.

Comparisons were made between treatment in the

first trimester and treatment during the third trimester
when dysmorphologic development cannot occur (Burtin et
a l .)

Three criteria were developed to be included in the

meta-analysis:

(1)

at least 10 women exposed to

metronidazole during the first trimester of pregnancy;

(2)

at least 10 women not exposed to metronidazole or only
during the third trimester;

(3)

all malformations observed

in live-born infants reported in each group (Burtin et
al.). Seven out of the 32 studies met all three criteria
for meta-analysis.
exposed women.

Studies ranged from 13 to over 1000

None of the odds ratios detected a

significantly increased risk of birth defects among infants
with exposure to metronidazole in the first trimester.
overall odds ratio of exposure versus no exposure during
the first trimester was 0.93.

There was no increased

teratogenic risk found (Burtin et al.)

The Centers for

Disease Control (CDC) and Prevention agrees with these
17

The

meta-analysis findings

(1998).

Metronidazole is the

preferred drug of choice in the treatment of BV in
pregnancy according to the CDC. Metronidazole eradicates
anaerobes through the activity of its hydroxy metabolite.
McDonald, O'^Loughlin, Vigneswaran, Jolley, and
McDonald (1994) conducted a randomized, double-blind,
placebo controlled study of metronidazole treatment in
pregnant women with BV.

Diagnosis was made with the use of

direct smears and low vaginal vault cultures.

The

antenatal clinic screened 2606 women for BV at 16-24 weeks
gestation.
BV.

Twenty-eight percent (739) tested positive for

Due to exclusions such as refused consent, age less

than 17, antibiotic therapy for vaginal discharge in the
preceding 2 weeks, allergy to metronidazole, placenta
previa with bleeding, premature rupture of membranes,
multiple gestation, and diabetes, the final sample size was
135 women.

Sixty-six with BV were treated with medication

and 69 were in the control (placebo) group.
Chi-square with Yates correction was used to test the
differences between the metronidazole group (n=66) and the
control placebo group

(n=69). McDonald et al.

(1994) also

calculated the odds ratio and 95% confidence intervals.
Sequential allocation from a list of random numbers, in
blocks of 16 was used for randomization to the control the
18

and experimental group.

Metronidazole effectively

suppressed BV in 43% of pregnant women compared with 25% in
the placebo group (p<.05) .

The odds ratio was 0.12 and the

confidence interval was 0.03-0.4

(McDonald et al.)

Hauth et al. (1995) found similar results in their
research.

Over 5000 pregnant women were screened to

participate and a total of 624 were enrolled.

Both groups

of women had similar characteristics such as weight,
parity, compliance, age, weeks of gestation, and Black
race.

Of the 624 participants, 433 received metronidazole

and 191 received the placebo.

A blocked randomization

schedule in a ratio of 2:1 was used (two women treated with
metronidazole for every one woman assigned to a placebo).
Similar diagnostic tests used by McDonald et al.
were performed to confirm BV.

(1994)

The same tests were repeated

two to four weeks after treatment was completed.

T-test,

chi-square, and Fisher's exact tests were used to analyze
the data.

Follow-up cultures on the group treated with

metronidazole showed a 25.6% decreased incidence of BV.
Initially, 40.7% had BV whereas 15.1% had BV post treatment
(p <.001).

The placebo group only had a 2% decrease.

Initially, 45.6% had BV and 43.6% tested positive after
treatment (p .71).
Morales, Schorr, and Albritton's
19

(1994) research

supports the previous study.
diagnosis of BV were similar.

Research methods and
Eighty pregnant women were

enrolled in a double-blind study.

Forty-four women were

treated with 250 mg of metronidazole orally, three times
daily, for seven days; and 36 women were given a placebo.
Demographic variables were comparable between the treatment
and the control group.
pregnant women.

This study did not re-culture the

It compared the number of hospital

admissions for preterm labor, gestational age at delivery,
birth weight, and premature rupture of membranes.
Data were analyzed with t tests and Chi-square tests.
Hospital admissions, low birth weight, and premature
rupture of membranes were shown to be statistically
significant with a p < .05.

Admissions for the metronidazole

group were 27% vs 78% for the placebo group.

Birth weight

less than 2500 g was 14% for the metronidazole-treated
group vs 33% for the placebo group.

Premature rupture of

membranes occurred in 5% of the metronidazole group vs 33%
in the placebo group.
Clindamycin is also effective against anaerobic
bacteria associated with BV and is not contraindicated in
the first trimester.

Clindamycin is a semisynthetic

antibiotic produced by a 7(S)-chloro-substitution of the
7®—hydroxyl group of the parent compound lincomycin.
20

It is

excreted by the liver and kidneys.
McGregor et al.

(1995) conducted a prospective,

controlled trial on the use of oral clindamycin in pregnant
women.

The study included 1138 pregnant women who were

divided into two groups.

The first group (559) was

enrolled at the initial prenatal visit before 22 weeks
gestation.

The second group (579) was followed beginning

between 22 and 29 weeks.

BV was diagnosed in 30.9% of the

women in group 1 and 33.6% in group 2 (p=.4) McGregor et
al.

Variables such as maternal age, ethnic background,

marital status, parity, diabetes, and antenatal bleeding
were similar for both groups.

Diagnosis was made through

microscopic examination and vaginal cultures.

Oral

clindamycin, 300 mg, twice daily was given to women testing
positive for infection.

Test of cure cultures were done

between 22 and 29 weeks gestation.
Descriptive statistics and logistic regression were
used to examine the effects of the risk factors.

Women in

both groups treated with oral clindamycin showed a cure
rate of 92.5% at the 2 to 4 week follow-up visit (McGregor
et al. 1995).

Treating BV in the second trimester reduced

the risk of premature labor to 25%.

A woman with BV and a

prior preterm delivery has a risk of premature delivery of
46.2%; p=.l, relative risk 0.54, 95% confidence interval
21

0-2 to 1.3).
The Centers for Disease Control released treatment
guidelines for bacterial vaginosis in January,^ 1998.
Recommendations include screening and treating high risk
pregnant women early in the second trimester.

High risk

women are those who have delivered premature infants.
risk women do not need to be screened unless
symptomatic.

Low

they are

Centers for Disease Control (1998) treatment

guidelines for high risk pregnant women are as follows :
Recommended:

Metronidazole 250 mg orally, three times

a day for 7 days
Alternative:

(1) Metronidazole 2 grams orally, in a

single dose or (2) Clindamycin 300 mg orally, twice
daily for 7 days
Treatment guidelines for low risk pregnant women are as
follows:

Recommended:

Metronidazole 250 mg orally,

three times a day for 7 days
Alternative:

(1)

Metronidazole 2 grams orally,

in a single dose or 2)

Clindamycin 300 mg orally,

twice a day for 7 days or (3)

Metronidazole gel,

0.75%, one full applicator (5g) intravaginally
twice a day for 5 days

(pp. 70-74)

Metronidazole doses have been lowered from the previous
500 mg dose to limit drug exposure to the fetus.
22

Also, the

use of clindamycin vaginal cream in pregnancy is no longer
recommended due to the possible link with increased preterm
deliveries.
Summary and Implications for Study
Numerous research studies have shown that BV increases
the incidence of premature rupture of membranes and preterm
labor.

Treatment of BV with oral metronidazole, vaginal

metronidazole, or oral clindamycin greatly reduces the
percentage of ruptured membranes and/or preterm labor.
Limitations of the previous studies include no comparison
of metronidazole vs clindamycin nor comparison of oral vs
vaginal route in the pregnant patient; therefore, it is not
known which drug and method of administration is most
beneficial to the pregnant woman.
Research Question
The purpose of this study was to examine the
relationship between the type of drug treatment of
bacterial vaginosis (oral metronidazole, vaginal
metronidazole, or oral clindamycin)

in pregnancy in females

ages 12 to 43 years old before 16 weeks gestation and the
recurrence rate between 35 and 37 weeks, using a
retrospective chart review.

The goal was to discover if

there were a difference in recurrence rates as reported in
the charts at 35 to 37 weeks gestation among pregnant women
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treated with either of the three treatment regimens.
Vaginal clindamycin will not be included in the study
because the Centers for Disease Control recommended
discontinuing its use in pregnancy (Mead & Eschenbach,
1998) .

Variables in the study will be the three types of

medication (oral metronidazole, vaginal metronidazole, and
oral clindamycin) and recurrence rates.
The answer would not only be helpful for health care
providers treating BV in pregnancy but would also benefit
the patient and fetus.

Using the most successful drug

could possibly eliminate years of health problems for a
neonate born prematurely.
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Chapter Three
METHODS
Research Design
This was a descriptive, correlational study using a
chart review to examine the relationship between
metronidazole (oral or vaginal) or oral clindamycin
treatment of BV in early pregnancy (before 16 weeks) and
the recurrence rate of BV at 35 to 37 weeks gestation.
A checklist developed by the investigator was used for
collecting data from the patientas chart-

Problems of

response biases are greatly reduced when obtaining data
from existing records

(Polit & Bungler, 1993).

One

limitation of this type of data collection is that of
assuming all information was assessed and entered correctly
into the chart.
A retrospective chart review was used to obtain needed
data.

Retrospective studies look at events that have

already occurred and try to determine what variables
contributed to the effect (Talbot, 1995).

An advantage is

that existing data in the patients chart may be used.
Sample and Setting
Information and data were collected from completed
patient charts in an obstetric and gynecology office.
Prior written approval to review all charts was obtained
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from the office manager (Appendix A) .

The office is

located in a mid western state and currently employs two
physicians and five certified nurse midwives.
providers care for pregnant women.

All

The population consists

mostly of Caucasians; however. Black, Hispanic, and Indian
women are also in this setting.

Payer mix is about 50%

private insurance and 50% public assistance.
Data collection was done after office hours and on
weekends.

This provided easier access to patient

information and did not interfere with patient flow.
charts were removed from the office.

No

Patient names or

identification were not collected to maintain
confidentially.

Approval for this study was obtained from

the Human Research Review Committee of Grand Valley State
University (Appendix B ) .
All patient charts in the office were audited to
identify the pregnant patients.

Charts from 1532 patients

pregnant in 1996, 1997 and 1998 were reviewed for the
appropriate information.

It was estimated that

approximately 4-6 charts could have been omitted if locked
in a providers private office although this was against
office policy.

Patients included in this study were those

testing positive for bacterial vaginosis on a routine
culture before 16 weeks gestation who then had a routine
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culture between 35 and 37 weeks gestation (N=186).
Exclusion criteria included diagnosis of vaginal group B
beta strepcocci(GBS)

infection prior to current

pregnancy(not re-cultured routinely at 35 to 37 weeks),
delivery before 37 weeks, and identification and treatment
of BV between 16 weeks and 35 weeks with current pregnancy.
Patients excluded for the above reasons do not have the
routine vaginal culture performed between 35 and 37 weeks.
Treatment with oral metronidazole, vaginal metronidazole,
or oral clindamycin was also a requirement for inclusion.
All providers use all drugs listed. All providers used the
same laboratory facilities and diagnostic standards.
Instruments
A check list developed by the researcher was used
(Appendix C).

Checklist categories included: patient

number, gestation at first culture, gestation at second
culture, culture results before 16 weeks, culture results
between 35 and 37 weeks, oral metronidazole use, vaginal
metronidazole use, oral clindamycin use, BV recurrence
before 35 weeks, and delivery before 37 weeks.

Demographic

patient information available in the chart such as parity,
age, and insurance status were also collected.
was identified with an assigned number.
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Each chart

Chapter 4
RESULTS
This descriptive, correlational study used a chart
review to examine the relationship between metronidazole
(oral or vaginal) or oral clindamycin treatment of BV in
early pregnancy.

Statistical analyses were done using SAS

statistical software to provide statistics.

Statistical

analysis was performed through chi-square which is used to
assess differences between two or more nominal-level
variables

(Polit & Hungler,

1993). Differences were

considered significant at p < .05.

Of the 1532 charts

reviewed, 271 pregnant women tested positive for BV.
Eight-five women were eliminated for the following reasons :
initial culture performed after 16 weeks gestation, no drug
treatment given with initial diagnosis, different drug
treatment used, positive diagnosis of GBS with previous or
current pregnancy, preterm delivery, and recurrence of BV
before 35 to 37 weeks gestation.

After review of the

criteria, 18 6 women were included in the study: 70 (37.6%)
treated with oral metronidazole, 56 (30.1%) treated with
vaginal metronidazole, and 60 (32.3%) treated with oral
clindamycin.

The three drug treatment groups did not

differ significantly with regard to age, parity, and
insurance, as summarized in Table 1.
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The mean age of women

was 23.9 (standard deviation [SD]=5.48) years with a range
of 12 to 43 years.
range of 1 to 6.

Mean parity was 2.2 (SD=1.17) with a
Seventy percent of the study group

received medicaid public assistance.

Table 1. Comparison by drug group of women

Drug
Age (yrs)

Me txon±da.zole

Metronidazole

Clindamycin

oral (d~70)

vaginal (n=56)

oral (n=SO)

Mean 23.8
SD

6.3

Mean 2.2

Parity

SD 1

Mean 24
SD

5.4

■ Significance

Mean 23.9
SD

MS

4.3

Mean 2.3

Mean 2.1

SD 1.3

SD 1.7

NS

Medicaid

51

41

39

NS

Private

19

15

21

NS

Insurance

Table two compares age, parity, and insurance in women
who had recurrence of BV between 35 and 37 weeks gestation.
Findings were similar to those reported in table one and
were not significant.
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Table 2. Women with positive BV cultures

Age (yrs)

Initial

Final

Group

Group

Mean 23.9

Mean 22.3

SD
Parity

5.48

Mean 2.2
SD 1.17

SD
Mean

Significance
•

5.24
1.8

SD

NS

NS

.71

Medicaid

70

73

NS

PI

30

27

NS

NS = not significant; SD = Standard deviation;
PI = private insurance
The recurrence rates for bacterial vaginosis between 35
and 37 weeks gestation were 20% for oral metronidazole, 18%
for vaginal metronidazole, and 15% for oral clindamycin.
As shown in Table 3, there was no statistically significant
difference in recurrence rates of BV at 35 to 37 weeks
gestation among pregnant women in the three treatment
groups.
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Table 3. Culture results at 35 to 37 weeks gestation

Positive.

Negative

Metronidazole-

14 (20%)

56 (80%)

Vaginal Metronidazole

10 (18%)

46 (82%)

9 (15%)

51 (85%)

Oral Clindamycin

Chi-square = .55; df = 2 ; p = .76
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Chapter 5
DISCUSSION AND IMPLICATIONS
Discussion
This was a study done to examine the relationship
between oral metronidazole^ vaginal metronidazole, or oral
clindamycin treatment of BV in early pregnancy and the
recurrence rate near term.

Age, parity, and insurance type

were comparable in each of the three drug groups.

All

women in the three test groups were cultured vaginally
before 16 weeks gestation and between 35 and 37 weeks
gestation.

There were 18 6 women who met the review

criteria to be included in this study.
The recurrence rate of BV when tested between 35 and
37 weeks gestation showed no differences when comparing the
three drug treatment groups.

Twenty percent of the oral

metronidazole group tested positive for BV while the
vaginal metronidazole group had 18% and oral clindamycin
had 15%.

Therefore, there was no relationship between the

use of oral metronidazole, vaginal metronidazole, and oral
clindamycin in the treatment of BV in early pregnancy
(before 16 weeks) and the recurrence rate of BV at 35 to 37
weeks gestation.

There were no studies found that compared

the three drugs used but the findings were comparable to
the research studies done b y McDonald et al.

(1994),

Morales, Schorr, and Albritton (1994), and McGregor et al.
(1995) as mentioned in chapter two.
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This study was built

on the previous author's research comparing any two of the
drugs mentioned.
Liioitations
Retrospective chart reviews help to control bias and
increase validity due to the fact that information
collection occurs afterward.

One limitation to this type

of study is the assumption that all information was entered
correctly into the medical record.

Making the assumption

that the patient completed the drug treatment as directed
is another limitation.

The time frame between vaginal

cultures was approximately 20 to 25 weeks.

Due to this

extended period of time, it would be difficult to determine
if the positive BV results at 35 to 37 weeks were due to
continuance of the same infection or an acquired new
infection of BV.

Comparison to findings in other research

studies was difficult due to the inability to find studies
with similar interests and variables.

And, because of the

small sample size, this study may not have sufficient power
to detect different recurrence rates among the three
treatment regimens.

Data stating what drug was used in the

treatment of BV in patient's who delivered before 35 weeks
gestation would have been helpful.
Efforts to control internal validity were as follows :
the same two laboratories were used; all patients were
cultured at first visit (before 16 weeks); charts were
reviewed by one person; the same criteria were used to
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determine diagnosis of BV; and, all three groups were
evaluated by the same personnel in the same office setting.
Bias was decreased because all pregnant women meeting the
criteria were included in the study.

A limitation to

external validity was that there was no control over highrisk behaviors such as frequent intercourse, multiple
partners, condom use, douching, and smoking.
Implications
Prevention of preterm deliveries is of utmost
importance throughout the world because it will help to
save the lives of preterm neonates, improve the health of
many children, and save millions of dollars.

Numerous

studies have shown that BV increases the incidence of
premature rupture of membranes, preterm labor,
chorioamnionitis, and postpartum endometritis.

Early

identification and optimal treatment of BV in pregnancy
will certainly contribute to the worldwide goals listed
above.
Nurse practitioners are frequently the ones providing
care to obstetrical patients.

Since they often make

decisions on whether to treat BV and which medication to
use if drug treatment is selected.

They have the ability

to have a positive influence on the preterm delivery rate.
Most practitioners would elect to prescribe the optimal
drug in the treatment of BV in pregnancy.

Results of this

study show little difference in recurrence rates of the
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three drugs used.

Therefore, decisions about which drug to

use in the treatment of BV in pregnancy must be
individualized.

A patient who appears hesitant to use oral

medications might only accept treatment via vaginal route
to reduce perceived drug exposure to the fetus.
metronidazole would be the choice for her.
medication is also a factor.

Vaginal

Cost of the

Generic oral metronidazole

averages $12.09 in the local area whereas vaginal
metronidazole costs $35.97 and oral clindamycin costs
$28.49.

A woman's inability to pay for a more expensive

prescription could lead to lack of treatment and increased
risk of preterm labor, premature rupture of membranes,
chorioamnionitis, and endometritis.

Many of the reported

side effects are similar for all three drugs such as
gastrointestinal upset, nausea, vomiting, and abdominal
cramps.

The use of oral or vaginal metronidazole can also

cause a metallic taste and vaginal candidiasis.

And,

clindamycin has been associated with pseudomembranous
colitis (2% to 10%).
Recommendations
Because BV has been associated with increased risk of
preterm labor and premature rupture of membranes, further
studies on a larger scale are needed to evaluate the
effectiveness of drug treatments used in pregnancy.
Additional research is needed on BV risk factors such as
low income, unmarried, and Black race.
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Research should

continue to evaluate the risks and benefits of medications
to the mother and fetus.

More focus needs to be placed on

prevention of preterm labor and premature rupture of
membranes rather than treatment of preterm labor once it
occurs.

We need to increase our understanding of BV and

its relationship to pregnancy, preterm labor, and premature
rupture of membranes.
Finally, we, as nurse practitioners, must remember our
training on health promotion and wellness.

Educate the

woman on risk factors for BV such as frequent change of
partners, frequent intercourse, condoms, smoking, and
douching.

Help her to keep the 'rings" of her Neuman

System's Model strong to maintain optimal health and
wellness.

The following are case reviews showing how to

maintain a strong Neuman Model.
Patient A is a 28 year old Black female who is 15 weeks
pregnant at the time of her initial physical.

The NP has

diagnosed BV through the routine vaginal culture.

Upon

interviewing the patient, it was discovered she douched
once or twice a week with plain water or a mixture of
vinegar and water.

Frequent douching is a culturally

encouraged practice among Black women in this area.

After

treatment with oral metronidazole and education on perineal
hygiene the infection resolved for the remainder of her
pregnancy.

This case involved primary, secondary, and

tertiary interventions which strengthened Patient A's line
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of defense.

Patient B is a 16 year old White female who is 16 weeks
pregnant.

She also had a diagnosis of BV at her first

office visit.

Upon interviewing the patient, she reveals a

recent change of partners with the occasional use of an
unknown type of condom.

Due to questionable compliance, a

one dose oral metronidazole treatment was given.

Education

included increasing her awareness of increased BV with
partner change and possibly the use of a new type of
condom.

Counseling on sexually transmitted diseases was

also discussed.

Treatment and education strengthened the

primary, secondary, and tertiary lines of resistence.

The

return to a normal vaginal ecosystem strengthened the
normal line of defense.

Decreasing the patients risk

factors (frequent partners and change in type of condom)
strengthened the flexible line of defense.

Patient B had

no further episodes of BV during her pregnancy and
delivered at 39 weeks gestation.
The selection of which researched drug to use makes
little difference in the efficacy rate in treating BV.
Education and health promotion consistent with Neuman^s
beliefs would serve a more valuable service.

Helping the

pregnant woman to understand her risk factors and the
importance of taking her medications as directed by her
health care provider, when appropriate, will help to keep
her lines of defense and lines of resistence strong to

37

protect her inner core.
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Appendix B
Human Research Committee Approval

G r a n d Xâluey
SX f^T E U N IV E R SrrY
I CAMPUS DRIVE • ALLENDALE. MICHIGAN 4 9 4 0 1 -9 4 0 3 • 616/895-6611

January 19, 1999

Karen Taylor
16661 SE 102 CTRd.
Summerfield, FL 32691

Dear Karen:

Your proposed project entitled "Does the M ethod o f Treating Bacterial Vaginosis in
Early Pregnancy Affect the Reoccurrence Rate Near Term?" has been reviewed. It
has been approved as a study which is exempt jfrom the regulations by section 46.101
o f the Federal Register 46( 16T-8336. January 26, 1981.

Sincerely,

Paul Huizenga, Chair
Human Research Review Committee
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Appendix C
BV Log Sheet

Patienr #
Age

Parity

Insurance

Gest/l"
culture
Culture
results
PO
Metronidazole
Vag.
Metronidazole
PO Clindamycin

Recurrence
<35wks
Delivery <
37wk
Culture
35-37wks
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